Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 4:42 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1033–1056 of 7,065 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Urological Disease Clear all
Completed Phase 1 Interventional

Phase I Dose Escalation Study for VIP152 in Patients With Advanced Cancer

NCT02635672
View directory record Official record
Conditions
Neoplasms
Interventions
VIP152 (BAY 1251152), VIP152 (BAY 1251152) 30 mg, Keytruda, VIP152 (BAY 1251152) 15 mg
Drug
Lead sponsor
Vincerx Pharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2024
U.S. locations
13
States / cities
Springdale, Arkansas • Louisville, Kentucky • Silver Spring, Maryland + 10 more
Source: ClinicalTrials.gov public record
Updated Nov 15, 2024 · Synced Oct 25, 2026, 4:42 PM EDT
Terminated Phase 2 Interventional

H+ Mobilization With Dialysate Bicarbonate Variation

NCT04020757
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
variation in dialysis bicarbonate, Zone Perfect bar
Device · Dietary Supplement
Lead sponsor
Tufts Medical Center
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 12, 2020 · Synced Oct 25, 2026, 4:42 PM EDT
Completed Not applicable Interventional Results available

Thulium vs. Hol:YAG Laser

NCT05808257
View directory record Official record
Conditions
Nephrolithiasis
Interventions
Thulium Fibre Laser, Holmium:Yttrium-Aluminum-Garnet
Device
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 29, 2025 · Synced Oct 25, 2026, 4:42 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Optimal Duration of Indwelling Urinary Catheter Following Pelvic Surgery

NCT01923129
View directory record Official record
Conditions
Urinary Retention
Interventions
Prazosin given 6 hours prior to catheter removal in the 24 hour group
Drug
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years and older
Enrollment
142 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2017
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 20, 2019 · Synced Oct 25, 2026, 4:42 PM EDT
Terminated Not applicable Interventional

Transcorporal Versus Standard Artificial Urinary Sphincter Placement

NCT02591381
View directory record Official record
Conditions
Urinary Stress Incontinence
Interventions
Artificial Urinary Sphincter Placement
Procedure
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older · Male only
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 4, 2018 · Synced Oct 25, 2026, 4:42 PM EDT
Recruiting No phase listed Observational

DESTINY-PANTUMOUR04

NCT07124000
View directory record Official record
Conditions
Adenocarcinoma (NOS), Anal Cancer, Bladder Cancer, Cervical Cancer, Endometrial Cancer, Esophageal Cancer, Gall Bladder Cancer, Gastrointestinal Stromal Tumour, Head and Neck Cancer, Liver Cancer, Melanoma, Mouth Cancer, Nasopharangeal Cancer, Neuroendocrine, Gastrointestinal Cancer, Ovarian Cancer, Pancreatic Cancer, Prostate Cancer, Renal Cell Carcinoma, Salivary Gland Cancer, Sarcoma, Small Cell Lung Cancer, Testicular Cancer, Throat Cancer, Thyroid Cancer, Urethral Cancer, Vaginal Cancer, Vulvar Cancer
Interventions
Trastuzumab deruxtecan
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
18
States / cities
Birmingham, Alabama • Bullhead City, Arizona • Casa Grande, Arizona + 15 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 25, 2026, 4:42 PM EDT
Completed No phase listed Observational

Blood Pressure Change and Outcome

NCT01330004
View directory record Official record
Conditions
Renal Disease, High Blood Pressure
Interventions
Not listed
Lead sponsor
Renal Research Institute
Other
Eligibility
18 Years to 88 Years
Enrollment
12,695 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2010
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 5, 2015 · Synced Oct 25, 2026, 4:42 PM EDT
Completed No phase listed Observational

Evaluation of Neutrophil Gelatinase-associated Lipocalin (NGAL) in Early and Evolving Acute Kidney Injury

NCT00445809
View directory record Official record
Conditions
Kidney Failure, Acute
Interventions
Not listed
Lead sponsor
Abbott RDx Cardiometabolic
Other
Eligibility
18 Years and older
Enrollment
355 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
10
States / cities
Denver, Colorado • Washington D.C., District of Columbia • Portland, Maine + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 4, 2009 · Synced Oct 25, 2026, 4:42 PM EDT
Completed Not applicable Interventional

Your Path to Transplant: A Randomized Control Trial of A Tailored Computer Education Intervention for Living Donor Kidney Transplant

NCT02181114
View directory record Official record
Conditions
End Stage Renal Disease
Interventions
Expert System Coaching
Behavioral
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
18 Years and older
Enrollment
815 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
2
States / cities
Los Angeles, California • Kingston, Rhode Island
Source: ClinicalTrials.gov public record
Updated Dec 28, 2023 · Synced Oct 25, 2026, 4:42 PM EDT
Completed No phase listed Observational Results available

Axonics SacRal NeuromodulaTIon System RegisTRY Study

NCT05064384
View directory record Official record
Conditions
Urinary Retention, Urinary Urge Incontinence, Urgency-Frequency, Fecal Incontinence
Interventions
Not listed
Lead sponsor
Axonics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
272 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
26
States / cities
Little Rock, Arkansas • Irvine, California • Redwood City, California + 21 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2025 · Synced Oct 25, 2026, 4:42 PM EDT
Enrolling by invitation No phase listed Observational Accepts healthy volunteers

AUD Biomarkers Study (Proteomic and Genomic Analysis of Biospecimens)

NCT05889806
View directory record Official record
Conditions
Oncology, Hematologic Malignancy, Gastro-Intestinal Disorder, Autoimmune Diseases, Pregnancy Related, Infectious Disease, Cardiovascular Diseases, Genitourinary Disease, Renal Disease
Interventions
Observational Study Only. NO Intervention.
Other
Lead sponsor
Audubon Bioscience
Industry
Eligibility
18 Years and older
Enrollment
10,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2043
U.S. locations
1
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Jun 5, 2023 · Synced Oct 25, 2026, 4:42 PM EDT
Completed Not applicable Interventional Results available

Impact of Decision Aids in Urogynecology

NCT04369404
View directory record Official record
Conditions
Pelvic Organ Prolapse, Stress Urinary Incontinence, Overactive Bladder
Interventions
Pelvic organ prolapse decision aid, Stress urinary incontinence decision aid, Overactive bladder decision aid
Behavioral
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 95 Years · Female only
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 16, 2024 · Synced Oct 25, 2026, 4:42 PM EDT
Completed Phase 3 Interventional Results available

Study Comparing TVT With TVT-SECUR for the Treatment of Stress Urinary Incontinence

NCT00534365
View directory record Official record
Conditions
Stress Urinary Incontinence
Interventions
tension-free vaginal tape, TVT-SECUR device
Device
Lead sponsor
The Cleveland Clinic
Other
Eligibility
21 Years and older · Female only
Enrollment
281 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
7
States / cities
Washington D.C., District of Columbia • Baltimore, Maryland • Durham, North Carolina + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2017 · Synced Oct 25, 2026, 4:42 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of CTAP101 to Treat Secondary Hyperparathyroidism in Stage 3 or 4 CKD and Vitamin D Insufficiency

NCT01651000
View directory record Official record
Conditions
Chronic Kidney Disease, Hyperparathyroidism, Secondary, Vitamin D Deficiency
Interventions
CTAP101 30 μg capsules, Sugar pill to CTAP101 30 μg capsules
Drug · Other
Lead sponsor
OPKO IP Holdings II, Inc.
Industry
Eligibility
18 Years and older
Enrollment
213 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Bannockburn, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 13, 2025 · Synced Oct 25, 2026, 4:42 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Comparing Voiding Trials After Midurethral Sling for Stress Incontinence

NCT02400034
View directory record Official record
Conditions
Stress Urinary Incontinence, Urethral Hypermobility, Cystocele
Interventions
Voiding trial
Other
Lead sponsor
Northwell Health
Other
Eligibility
18 Years and older · Female only
Enrollment
112 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Great Neck, New York
Source: ClinicalTrials.gov public record
Updated Oct 21, 2016 · Synced Oct 25, 2026, 4:42 PM EDT
Terminated Not applicable Interventional

Effect of Exercise and Biofeedback on Symptoms of Incontinence in Women With Stress Urinary Incontinence

NCT01337193
View directory record Official record
Conditions
Stress Urinary Incontinence
Interventions
Pelvic floor exercises with biofeedback, Pelvic floor muscle exercises
Other
Lead sponsor
Texas Woman's University
Other
Eligibility
20 Years and older · Female only
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Nov 14, 2014 · Synced Oct 25, 2026, 4:42 PM EDT
Completed Phase 4 Interventional Results available

Effect of Increasing Doses of Cystine Binding Thiol Drugs on Cystine Capacity in Patients With Cystinuria

NCT02125721
View directory record Official record
Conditions
Cystinuria
Interventions
Tiopronin 1g per day, Tiopronin 2g per day, Tiopronin 3g per day
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 80 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 23, 2021 · Synced Oct 25, 2026, 4:42 PM EDT
Terminated Phase 2 Interventional

An Open-Label, Long-term Study of GFB-887 in Patients With Glomerular Kidney Diseases

NCT04950114
View directory record Official record
Conditions
Kidney Diseases, Glomerulosclerosis, Focal Segmental Nephrosis, Lipoid Urologic Disease, Glomerulonephritis, Nephritis, Nephrosis
Interventions
GFB-887
Drug
Lead sponsor
Goldfinch Bio, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
17
States / cities
Los Angeles, California • Northridge, California • Victorville, California + 14 more
Source: ClinicalTrials.gov public record
Updated Nov 15, 2022 · Synced Oct 25, 2026, 4:42 PM EDT
Not yet recruiting Not applicable Interventional

Prospective Multi-center Study Comparing Pulsed Tm:YAG Laser to Pulse Modulated Holmium Laser in the Treatment of Nephrolithiasis With FANS Access Sheaths

NCT07516106
View directory record Official record
Conditions
Kidney Stone
Interventions
Moses Holmium:YAG laser, Thulium:YAG laser
Device
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
2
States / cities
Phoenix, Arizona • New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 7, 2026 · Synced Oct 25, 2026, 4:42 PM EDT
Recruiting Phase 1Phase 2 Interventional

A Phase 1/2 Study of NKX019 in Subjects With Autoimmune Disease (Ntrust-1)

NCT06557265
View directory record Official record
Conditions
Lupus Nephritis, Primary Membranous Nephropathy
Interventions
NKX019, Fludarabine, Cyclophosphamide
Drug
Lead sponsor
Nkarta, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
17
States / cities
Little Rock, Arkansas • Tustin, California • Gainesville, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Oct 25, 2026, 4:42 PM EDT
Withdrawn No phase listed Observational

Evaluation of Nephrogenic Systemic Fibrosis (NSF) in Patients With Chronic Kidney Disease Following OptiMARK Injection

NCT00811863
View directory record Official record
Conditions
Nephrogenic Systemic Fibrosis, Renal Insufficiency
Interventions
Not listed
Lead sponsor
Guerbet
Industry
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Youngstown, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 2, 2017 · Synced Oct 25, 2026, 4:42 PM EDT
Terminated Phase 2 Interventional Results available

Multi-center Trial of ESK981 in Combination With Nivolumab in Patients With Metastatic Renal Cell Carcinoma

NCT03562507
View directory record Official record
Conditions
Renal Cell Carcinoma, Metastatic
Interventions
ESK981, Nivolumab
Drug
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated May 20, 2024 · Synced Oct 25, 2026, 4:42 PM EDT
Completed No phase listed Observational

Prevalence of Proteinuria and Chronic Kidney Disease in Pediatric HIV-Infected Patients

NCT00153621
View directory record Official record
Conditions
Chronic Kidney Failure, AIDS-Associated Nephropathy, HIV Infections
Interventions
Not listed
Lead sponsor
Children's National Research Institute
Other
Eligibility
1 Year to 21 Years
Enrollment
320 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated May 5, 2008 · Synced Oct 25, 2026, 4:42 PM EDT
Completed Phase 2 Interventional

The Effect of Human Recombinant Erythropoietin in Acute Renal Failure

NCT03102021
View directory record Official record
Conditions
Acute Kidney Injury
Interventions
erythropoietin, saline
Drug
Lead sponsor
North Texas Veterans Healthcare System
Federal
Eligibility
21 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Apr 5, 2017 · Synced Oct 25, 2026, 4:42 PM EDT